Welcome to our dedicated page for Ideaya Biosciences SEC filings (Ticker: IDYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IDEAYA Biosciences, Inc. (NASDAQ: IDYA) SEC filings page aggregates the company’s regulatory disclosures, including current reports on Form 8-K and other Exchange Act filings. These documents provide structured information on material events, financial results, collaborations, and governance decisions that affect the precision oncology business.
IDEAYA uses Form 8-K to report key developments such as quarterly financial results, material licensing agreements, and changes in major collaborations. For example, 8-K filings describe the exclusive license agreement with Servier for rights to darovasertib outside the United States, GlaxoSmithKline’s election to terminate a collaboration covering the Werner Helicase (IDE275) and Pol Theta (IDE705) programs, and positive clinical data from trials of darovasertib, IDE849, and IDE397. Other 8-Ks document annual meeting voting results, executive appointments, and inducement equity grants under Nasdaq Listing Rule 5635(c)(4).
Filings also identify IDEAYA’s listing on The Nasdaq Global Select Market under the symbol IDYA and confirm that its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934. Investors can review these filings to understand how IDEAYA structures its collaborations, recognizes collaboration revenue, and discloses pipeline milestones and regulatory interactions.
On Stock Titan, IDEAYA’s SEC filings are updated as they are posted to EDGAR and can be paired with AI-powered summaries that explain the significance of each document in accessible language. Users can quickly scan material terms of agreements, track clinical and regulatory updates reported under Item 8.01, and monitor financial disclosures reported under Item 2.02, without having to parse every line of the original filing.
IDEAYA Biosciences (Nasdaq: IDYA) filed an 8-K disclosing a material C-suite change. On June 26 2025, the Board appointed Joshua Bleharski, Ph.D. as Chief Financial Officer and Principal Financial Officer under Item 5.02. The filing states the appointment is effective immediately and made pursuant to Section 16(a)-1(f) of the Exchange Act.
No resignations, compensation terms, financial guidance or other business updates were provided. Investors should monitor upcoming filings for any strategic or financial initiatives led by the new CFO.
IDEAYA Biosciences (IDYA) director Wendy L. Yarno received a stock option grant for 20,000 shares of common stock on June 24, 2025. The options were granted with an exercise price of $21.78 per share and will expire on June 24, 2035.
Key terms of the option grant:
- Vesting occurs at the earlier of: (1) first anniversary of grant date or (2) immediately before the next Annual Meeting
- Vesting is contingent on continued Board service
- The options represent a direct ownership form
This Form 4 filing was submitted by Andres Ruiz Briseno as attorney-in-fact for Yarno on June 26, 2025, meeting the SEC's two-day reporting requirement for insider transactions.
IDEAYA Biosciences (IDYA) Director Jeffrey Stein received a new stock option grant on June 24, 2025. The grant consists of 20,000 stock options with an exercise price of $21.78 per share.
Key details of the option grant:
- Expiration date: June 24, 2035
- Vesting schedule: 100% vests on earlier of (i) first anniversary of grant date or (ii) immediately before next Annual Meeting
- Vesting contingent on continued Board service
This Form 4 filing, signed by Attorney-in-Fact Andres Ruiz Briseno on June 26, 2025, represents standard equity compensation for non-employee director service. The grant aligns the director's interests with shareholders through long-term equity ownership.
IDEAYA Biosciences (IDYA) director Malcolm Garret Hampton received a new stock option grant on June 24, 2025. The grant consists of:
- Options to purchase 20,000 shares of common stock
- Exercise price set at $21.78 per share
- Expiration date of June 24, 2035
The options feature an accelerated vesting schedule, with 100% vesting occurring at the earlier of: (1) the first anniversary of the grant date, or (2) immediately before the next Annual Meeting, contingent on Hampton's continued board service. This grant appears to be part of the company's standard director compensation program. The transaction was reported via Form 4 filed by Hampton's attorney-in-fact, Andres Ruiz Briseno.
IDEAYA Biosciences (IDYA) director Terry J. Rosen received a stock option grant on June 24, 2025. The key details of this insider transaction include:
- Granted 20,000 stock options to purchase common stock at an exercise price of $21.78 per share
- Options will expire on June 24, 2035
- Vesting schedule: 100% vests on the earlier of: - First anniversary of grant date - Immediately before next Annual Meeting
- Vesting is contingent on continued board service
This grant represents standard non-employee director compensation and aligns the director's interests with shareholders through long-term equity ownership. The filing was submitted via attorney-in-fact Andres Ruiz Briseno on June 26, 2025.
IDEAYA Biosciences held its 2025 Annual Meeting of Stockholders on June 24, 2025, where shareholders voted on three key proposals:
- Director Elections: Jeffrey L. Stein, Ph.D. was elected with strong support (69,077,770 votes for), while Scott W. Morrison received more divided support (42,132,938 votes for, 34,900,780 withheld)
- Auditor Ratification: PricewaterhouseCoopers LLP was approved as the independent auditor for FY2025 with overwhelming support (79,645,454 votes for)
- Executive Compensation: The non-binding advisory vote on executive compensation passed but showed significant dissent (59,798,805 for vs 17,040,207 against)
Out of 87,577,550 total outstanding shares eligible to vote, the meeting saw substantial shareholder participation. The split vote on Morrison's directorship and significant opposition to executive compensation suggests some shareholder concerns about governance and compensation practices.